Showing results (1-10 of 63) with videos related to
Sort By:
Pageof 7
Current Opinion in Virology|February 22, 2016
HSV antivirals - current and future treatment optionsAlexander Birkmann, Holger ZimmermannAntiviral Research|June 10, 2008
Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicitySubhajit Biswas, Laurence S Tiley, Holger Zimmermann, et al.The Journal of Antimicrobial Chemotherapy|May 11, 2010
Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitorSoumi Sukla, Subhajit Biswas, Alexander Birkmann, et al.Antiviral Research|September 12, 2013
Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivirHugh J Field, Meei-Li Huang, Elizabeth M Lay, et al.Clinical Pharmacology in Drug Development|May 16, 2024
Evaluation of the Clinical Drug-Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail ApproachMichiel de Vries, Susanne Bonsmann, Jörg Pausch, et al.Antiviral Research|April 28, 2010
Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutantSoumi Sukla, Subhajit Biswas, Alexander Birkmann, et al.Clinical Pharmacology in Drug Development|January 8, 2024
Mass Balance and Metabolite Profile after Single and Multiple Oral Doses of Pritelivir in Healthy SubjectsSusanne Bonsmann, David McCormick, Jörg Pausch, et al.Journal of Medicinal Chemistry|March 9, 2017
Lead Development of Thiazolylsulfonamides with Carbonic Anhydrase Inhibitory ActionFabrizio Carta, Alexander Birkmann, Tamara Pfaff, et al.Clinical Pharmacology in Drug Development|September 25, 2024
Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Pritelivir and Its MetabolitesKatharina Erb-Zohar, Susanne Bonsmann, Jörg Pausch, et al.Clinical Pharmacology in Drug Development|March 2, 2023
First-in-Human, Single- and Multiple-Ascending-Dose, Food-Effect, and Absolute Bioavailability Trials to Assess the Pharmacokinetics, Safety, and Tolerability of Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor Against Herpes Simplex Virus in Healthy SubjectsDirk Kropeit, Susanne Bonsmann, Oliver von Richter, et al.Pageof 7